Nuvilex (NASDAQ:PMCB – Get Free Report) released its earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, Zacks reports.
Nuvilex Trading Up 1.9%
NASDAQ:PMCB traded up $0.02 during trading hours on Thursday, hitting $0.84. The company had a trading volume of 529,527 shares, compared to its average volume of 889,598. Nuvilex has a 1 year low of $0.63 and a 1 year high of $1.90. The company has a market cap of $5.71 million, a P/E ratio of -1.56 and a beta of 0.06. The company has a 50-day moving average of $0.91 and a 200 day moving average of $0.98.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
Nuvilex Company Profile
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
Recommended Stories
- Five stocks we like better than Nuvilex
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500
- Best Aerospace Stocks Investing
- Forget the Chips: 4 Industrial Plays for the AI Rebound
- What is Short Interest? How to Use It
- MongoDB Could Hit Record Highs—But You’ll Need to Move Fast
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
